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Abstract
Background: The results of meta-analyses conducted by previous association studies between total homocysteine
and schizophrenia suggest that an elevated total homocysteine level is a risk factor for schizophrenia. However,
observational studies have potential limitations, such as confounding and reverse causation. In the present study, we
evaluated a causal relationship between plasma total homocysteine and schizophrenia by conducting a Mendelian
randomization analysis.
Methods: We used the MTHFR C677T polymorphism as an instrumental variable, which affects the plasma total
homocysteine levels. To calculate the risk estimate for the association of this single nucleotide polymorphism (SNP)
with schizophrenia, we conducted a meta-analysis of case–control studies that comprise a total of 11,042 patients with
schizophrenia and 14,557 control subjects. We obtained an estimate for the association of this SNP with the plasma
total homocysteine levels from a meta-analysis of genome-wide association studies comprising 44,147 individuals.
Results: By combining these two estimates, we demonstrated a significant effect of the plasma total homocysteine on
schizophrenia risk, representing an OR of 2.15 (95 % CI = 1.39–3.32; p = 5.3 x 10−4) for schizophrenia per 1-SD increase
in the natural log-transformed plasma total homocysteine levels.
Conclusions: We provided evidence of a causal relationship between the plasma total homocysteine and
schizophrenia, and this result will add insight into the pathology and treatment of schizophrenia.
Background
Homocysteine is a key substance in the methionine cycle,
which is involved in one-carbon methyl group-transfer
metabolism. The methylenetetrahydrofolate reductase
(MTHFR) C677T (rs1801133) polymorphism is a well-
characterized genetic variant. C677T of the MTHFR gene
results in amino-acid substitution (Ala222Val), and causes a
reduction of enzyme activity and higher plasma total homo-
cysteine levels [1]. The association of this variant with the
plasma total homocysteine was confirmed by a recent
meta-analysis of genome-wide association studies [2]. Previ-
ous meta-analyses of association studies between total
homocysteine, which includes plasma and serum total
homocysteine, and schizophrenia suggest that an elevated
total homocysteine level is a risk factor for schizophrenia
[3, 4]. However, observational studies have potential limita-
tions, such as confounding, reverse causation, and selection
bias. In fact, several findings of observational studies have
been shown to be spurious causes by subsequent random-
ized controlled trials, such as hormone replacement therapy
in coronary heart disease, β carotene in lung cancer, and
vitamin E and vitamin C in cardiovascular disease [5]. In
addition to genetic variants [2], many determinants that
affect plasma total homocysteine concentrations, including
physiologic determinants, such as age and sex, lifestyle de-
terminants, such as vitamin intake, smoking and coffee,
and clinical conditions, such as folate deficiency and renal
failure, have been reported [6]. Moreover, whether hyper-
homocysteine itself causes schizophrenia or schizophrenia
causes hyper-homocysteine has not been clarfied. For
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examples, the high prevalence of smoking and decreased
folate levels in patients with schizophrenia have been
reported [7–10], both of which are known to be associated
with increased plasma total homocysteine concentrations.
Mendelian randomization analysis, which uses genetic
variants as instrumental variables for exposures of inter-
est, can overcome problems of confounding and reverse
causality, and is a useful method for assessing causal
relationships in epidemiological studies [11–16].
Mendelian randomization refers to the random alloca-
tion of alleles at the time of gamete formation. A specific
genotype carried by a person results from two such ran-
domized transmission, one from the paternally inherited
allele and the other from the maternally allele. As a conse-
quence of these randomizations, genotypes are not ex-
pected to be associated with known or unknown
confounders for any outcome of interest, except those
lying on the causal pathway between the genotype and the
outcome. This allows analyzing the genotype-risks factor
association (in this case, the genotype-the plasma total
homocysteine) and the genotype-outcome association (in
this case, the genotype-schizophrenia) in an unconfounded
manner [13]. By combining the results of the genotype-risk
factor association and the genotype-outcome association,
one can get an estimate of the risk factor-outcome associ-
ation (in this case, the plasma total homocysteine-
schizophrenia). In addition, genetic variants are equivalent
to lifetime differences in risk factor (in this case, the plasma
total homocysteine), and indicate the long term effects of
risk factor on disease (in this case, schizophrenia). They
therefore generate more realistic estimates of causal effects
between risk factor and disease [5]. The Mendelian
randomization approach has similar properties to the ana-
lysis of the intention to treat in randomized controlled trials
[5, 17], and this approach has provided new insights into
the pathology of several diseases, such as cardiovascular
disease, diabetes, and Parkinson disease [18–26].
In this study, we evaluated a causal relationship be-
tween plasma total homocysteine and schizophrenia by
conducting a Mendelian randomization analysis based
on the MTHFR C677T polymorphism as an instrumen-
tal variable.
Methods
The estimate for gene-schizophrenia association
The risk estimate for the gene-schizophrenia association of
the T allele of the MTHFR C677T polymorphism (OR scz/
per T-allele) was evaluated by conducting a meta-analysis of
case–control studies with the random-effect model by
‘metafor’, an R package. Eligible studies were identified
using SZGene [27] and the PubMed search engine with
the terms “Methylenetetrahydrofolate reductase” or
“MTHFR” or “schizophrenia”. We also conducted an add-
itional manual search of reference lists and review articles.
Studies meeting the following criteria were included for
meta-analysis: (1) performed a case–control study (i.e.,
schizophrenia versus control), (2) provided data on geno-
type frequencies, and (3) was published in the English lan-
guage. The two reviewers (Kinoshita M and Nishi A)
selected the articles independently according to the above
inclusion criteria, and then discussed the articles until they
reached a consensus on every study used for the meta-
analysis. Heterogeneity was assessed using the I2 statistic,
and publication bias was assessed using funnel plots and a
regression test [28]. OR and 95 % confidence intervals (CI)
were calculated by ‘metafor’, an R package. Finally, we used
36 case–control studies from 32 papers for a total of
11,042 patients with schizophrenia and 14,557 control
subjects [4, 29–59] based on a Preferred Reporting Items
for Systematic Review and Meta-Analyses (PRISMA) flow-
chart [60] (Additional file 1: Figure S1).
The estimate for gene-plasma total homocysteine
association
We used a pooled estimate of per-T allele standardized β
coefficient (0.158) of the effect of the MTHFR C677T
polymorphism on the natural log-transformed plasma
total homocysteine levels (beta hcy/per T-allele) from a re-
cent meta-analysis of genome-wide association studies
comprising 44,147 individuals [2].
Mendelian randomization analysis
We calculated a Mendelian randomization estimate of
the effect of the plasma total homocysteine levels on the
risk of schizophrenia (OR scz/hcy) as log OR scz/hcy = (log
OR scz/per T-allele)/ beta hcy/per T-allele, as in previous
studies [4, 21]. Log OR scz/hcy is the (log) increase of
schizophrenia risk by 1-standard deviation (SD) increase
in the natural log-transformed plasma total homocysteine
(plasma total homocysteine-schizophrenia association).
Log OR scz/per T-allele is the (log) increase in schizophrenia
risk per T allele of the MTHFR C677T polymorphism
(gene-schizophrenia association). Beta hcy/per T-allele is the
number of SD differences in the natural log-transformed
plasma total homocysteine levels per the T allele (SD/
allele) (gene-plasma total homocysteine association).
Results
The pooled OR scz/per T-allele was 1.13 (95 % CI = 1.06–1.22;
p = 5.9 x 10−4 in the random-effects model) with significant
heterogeneity (I2 = 66.1 %; p < 0.05; Fig. 1). The funnel plot
analysis indicated no evidence of publication bias in this
meta-analysis (p > 0.05). By combining two pooled esti-
mates, OR scz/per T-allele from a meta-analysis of 36 case–
control studies and beta hcy/per T-allele from a meta-analysis
of genome-wide association studies by van Meurs and col-
leagues [2], we found a significant effect of the plasma total
homocysteine on schizophrenia risk in the Mendelian
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randomization analysis, representing an OR scz/hcy of 2.15
(95 % CI = 1.39–3.32; p = 5.3 x 10−4) for schizophrenia per
1-SD increase in the natural log-transformed plasma total
homocysteine levels (Fig. 2).
Discussion
By conducting a Mendelian randomization approach, we
demonstrated that increased plasma total homocysteine
concentration levels may be causally associated with an
increased risk of developing schizophrenia. Our finding is
consistent with the result of our recent paper that used a
Japanese cohort [4]. Our finding is also supported by a
longitudinal study in which elevated maternal levels of
homocysteine levels during the third trimester were found
to increase the risk of schizophrenia in the offspring [61].
Furthermore, the benefits of homocysteine-reducing strat-
egies in schizophrenia have been reported in previous stud-
ies with randomized, double-blind, and placebo-controlled
designs. Levine et al. [62] reported an improvement in the
clinical symptoms of the patients with schizophrenia and
hyper-homocysteinemia (over 15umol/L) who were treated
with folate, vitamin B12, and pyridoxine. Roffman et al. [63]
reported an improvement in the negative symptoms of
patients with schizophrenia who were treated with folate
and vitamin B12 when several functional genetic variants
were taken into account.
Hyper-homocysteine has also been observed in car-
diovascular disease [64], and yet randomized trials have
failed to demonstrate benefit of homocysteine-lowering
intervention on cardiovascular outcomes [18, 65]. The
discordant results from observational studies and ran-
domized trials might be caused by the limited period of
the randomized trials, the effects of aspirin and other
antiplatelet drugs [66], confounding factors, or reverse
causation. Several papers had not found evidence in
support of a causal association between homocysteine
and cardiovascular disease [2, 18].
There are some limitations to the present Mendelian
randomization analysis. One is the number of genetic
variants. We used one polymorphism as the instrumental
Fig. 1 A meta-analysis of genetic association studies between the MTHFR C677T polymorphism and schizophrenia. Thirty six case–control studies
were used for the meta-analysis (N = 25,599). The pooled OR per T allele of the MTHFR C677T polymorphism on schizophrenia risk was 1.13 (95 %
CI = 1.06–1.22; p = 5.9 x 10−4) in the random-effects model with significant heterogeneity among studies (I2 = 66.1 %; p < 0.05)
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variable that affects the plasma total homocysteine con-
centrations. However, a recent meta-analysis of genome
wide association studies of the plasma total homocysteine
has identified several genetic variants [2]. Further replica-
tion studies will be needed using multiple genetic variants
related to the plasma total homocysteine levels, because
using multiple instruments increases the precision of the
instrumental variable estimates [14]. The second is a
reintroduced confounding through pleiotropy [12, 14, 15].
Pleiotropy is defined as the phenomenon in which a single
locus affects two or more distinct phenotypic traits [67].
The MTHFR C677T polymorphism may directly
influence more than one post-transcriptional process.
The third is population stratification [12, 14, 15]. When
we estimated both gene-schizophrenia association and
gene-plasma total homocysteine association, we used
a cohort that was composed of a mixed population.
The fourth is a developmental compensation [12, 15].
During development, compensatory process may be
generated that counter the phenotypic perturbation
consequent on the genetic variant utilized as an instru-
ment [15].
Conclusions
In summary, we provided evidence of a causal relationship
between the plasma total homocysteine and schizophrenia
by conducting a Mendelian randomization approach.
However, our findings have to be interpreted with caution
because of the limitations, such as pleiotropy and popula-
tion stratification.
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Fig. 2 Graphical representation of the Mendelian randomization approach. The risk estimate for the gene-schizophrenia association of the T allele
of the MTHFR C677T polymorphism was obtained from the present meta-analysis of previous genetic association studies that cover a total of
25,599 individuals (11,042 cases and 14,557 controls). To establish the gene-homocysteine association, we took a pooled estimate of the effect of the
MTHFR C677T polymorphism on the plasma total homocysteine levels from a recent meta-analysis of previous genome-wide association studies, including
44,147 individuals (van Meurs et al. [2]). From these two estimates, we calculated a Mendelian randomization estimate of the effect of the plasma total
homocysteine levels on the risk of schizophrenia. This estimate represented the OR for schizophrenia risk per 1-SD increase in the log-transformed plasma
total homocysteine levels
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Additional file
Additional file 1: Figure S1. A flowchart of study selection using a
PRISMA checklist. The number of records identified through database
searching was 234. After adjusting for duplicates, 113 studies were
remained. By checking the titles, we excluded studies published in
languages other than English (8 studies), review and case reports (13
studies), and studies using animal samples (4 studies). By reviewing
abstracts, we excluded studies which were not case–control studies (34
studies), a study using cases without schizophrenia (1 study), and a study
examining a different single-nucleotide polymorphisms (1 study). After
these steps, 52 studies were remained. Of the 52 studies that were
subjected to full-text inspection, we further excluded studies which
did not contain original data (8 studies), studies which did not compare
cases with controls (5 studies), a study which did not contain the details of
samples (1 study), a study using cases without schizophrenia (1 study), and
studies which were suspected overlapping of samples (5 studies). Finally, 32
papers, including 36 case–control studies, were remained.
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